Overview Financials News + Filings Key Docs Charts Ownership
|
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| | 20-F | 20-F | 20-F | 20-F | 20-F | S-1/A |
| Revenues: |
| All Other Segments | | 105.4 | | 50.2 | 39.7 | 38.2 |
| Patient Monitoring And Life Support Devices | | 469.7 | | 386.7 | 316.2 | 278.1 |
| Medical Imaging Systems | | 303.4 | | 221.6 | 173.2 | 162.5 |
| In-Vitro Diagnostic Products | | 335.5 | | 222.3 | 175.2 | 155.4 |
| Total revenues | 1,322.8 | 1,214.0 | 1,060.1 | 880.7 | 704.3 | 634.2 |
| Revenue growth [+] | 9.0% | 14.5% | 20.4% | 25.1% | 11.1% | |
| All Other Segments | | | | 26.5% | 3.8% | |
| Patient Monitoring And Life Support Devices | | | | 22.3% | 13.7% | |
| Medical Imaging Systems | | | | 28.0% | 6.6% | |
| In-Vitro Diagnostic Products | | | | 26.8% | 12.8% | |
| Cost of goods sold | 584.3 | 527.4 | 459.4 | 394.3 | 303.3 | 280.3 |
| Gross profit | 738.5 | 686.6 | 600.7 | 486.4 | 401.0 | 353.9 |
| Gross margin | 55.8% | 56.6% | 56.7% | 55.2% | 56.9% | 55.8% |
| Selling, general and administrative [+] | 137.0 | 348.9 | 116.2 | 237.4 | 184.2 | 153.7 |
| Sales and marketing | | 220.6 | | 167.0 | 123.0 | 106.1 |
| General and administrative | 137.0 | 128.3 | 116.2 | 70.3 | 61.2 | 47.5 |
| Research and development | | 127.5 | | 82.0 | 60.3 | 58.4 |
| Other operating expenses | 6.8 | | 4.2 | | 0.9 | 1.2 |
| EBITDA [+] | | 263.5 | | 199.8 | 181.8 | 167.5 |
| EBITDA growth | 125.7% | -45.1% | 140.3% | 9.9% | 8.6% | |
| EBITDA margin | 45.0% | 21.7% | 45.3% | 22.7% | 25.8% | 26.4% |
| Depreciation | -21.3 | 33.5 | -13.1 | 23.2 | 18.8 | 18.7 |
| EBITA | 616.0 | 230.0 | 493.4 | 176.6 | 163.0 | 148.8 |
| EBITA margin | 46.6% | 18.9% | 46.5% | 20.1% | 23.1% | 23.5% |
| Amortization of intangibles | 21.3 | 19.7 | 13.1 | 9.6 | 7.5 | 8.1 |
| EBIT [+] | 594.7 | 210.2 | 480.2 | 167.0 | 155.6 | 140.6 |
| EBIT growth | 182.9% | -56.2% | 187.5% | 7.4% | 10.6% | |
| EBIT margin | 45.0% | 17.3% | 45.3% | 19.0% | 22.1% | 22.2% |
| Non-recurring items [+] | | | 0.3 | | | |
| Asset impairment | | | 0.3 | | | |
| Interest income, net [+] | 39.0 | 30.7 | 30.8 | 19.4 | 8.7 | 1.8 |
| Interest expense | 6.4 | 6.3 | 4.1 | 1.4 | 2.9 | 4.8 |
| Interest income | 39.0 | 37.0 | 30.8 | 20.8 | 11.6 | 6.6 |
| Other income (expense), net | -392.8 | 3.9 | -287.0 | 3.1 | 8.8 | 25.5 |
| Pre-tax income | 234.5 | 244.8 | 219.7 | 189.6 | 173.1 | 168.0 |
| Income taxes | 35.5 | 14.3 | 37.4 | 22.6 | 17.6 | 28.8 |
| Tax rate | 15.1% | 5.8% | 17.0% | 11.9% | 10.2% | 17.1% |
| Minority interest | 5.7 | 5.8 | 2.1 | 0.3 | | |
| Net income | 193.3 | 224.8 | 178.1 | 166.6 | 155.5 | 139.2 |
| Net margin | 14.6% | 18.5% | 16.8% | 18.9% | 22.1% | 21.9% |
| |
| Basic EPS [+] | $1.65 | $1.91 | $1.53 | $1.45 | $1.37 | $1.28 |
| Growth | -13.5% | 25.1% | 5.5% | 5.7% | 6.7% | |
| Diluted EPS [+] | $1.63 | $1.87 | $1.49 | $1.41 | $1.32 | $1.23 |
| Growth | -12.8% | 25.9% | 5.7% | 6.4% | 7.4% | |
| |
| Dividends per share [+] | $0.50 | $0.50 | $0.40 | $0.30 | $0.20 | $0.20 |
| Growth | -0.1% | 26.3% | 32.7% | 49.3% | 0.9% | |
| |
| Shares outstanding (basic) [+] | 117.1 | 117.7 | 116.7 | 115.3 | 113.6 | 108.6 |
| Growth | -0.6% | 0.8% | 1.3% | 1.4% | 4.7% | |
| Shares outstanding (diluted) [+] | 118.4 | 120.1 | 119.8 | 118.4 | 117.6 | 113.0 |
| Growth | -1.4% | 0.2% | 1.2% | 0.7% | 4.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|